MDM2与p16在血管平滑肌脂肪瘤中的表达
本研究用免疫组化检测MDM2、p16、HMB45和Melan-A在血管平滑肌脂肪瘤(AML)与腹膜后高分化/去分化脂肪肉瘤(WDLS/DDLS)及脂肪瘤中的表达,以评估其鉴别诊断价值。AML中MDM2局灶表达见于40%病例、p16局灶或弥漫表达见于60%病例;WDLS/DDLS中MDM2和p16分别有91%和97%呈局灶或弥漫表达。单独MDM2或p16不能可靠区分AML与脂肪瘤、WDLS/DDLS,联合HMB45、Melan-A、MDM2和p16并结合形态学有助于鉴别,疑难病例应行MDM2 FISH检测。
要点
- HMB45和Melan-A在AML中阳性而脂肪瘤及WDLS/DDLS均不表达,是鉴别的关键标志物。
- WDLS/DDLS常见MDM2(91%)和p16(97%)局灶或弥漫表达,但AML也可局灶表达MDM2和p16。
- 单独MDM2或p16不能排除AML或脂肪瘤,疑难病例需行MDM2 FISH检测。
核心结论
- 单独MDM2表达不能排除AML或脂肪瘤诊断,单独p16也不能区分AML和普通脂肪瘤与WDLS/DDLS。
- 结合形态学与HMB45、Melan-A、MDM2和p16免疫组化组合有助于鉴别AML与WDLS/DDLS或脂肪瘤。
- 疑难病例应行MDM2荧光原位杂交(FISH)检测。
研究设计与样本
- 对AML、WDLS/DDLS及脂肪瘤行MDM2、p16、HMB45和Melan-A免疫组化分析以评估鉴别诊断效用。
主要发现
- AML中MDM2局灶表达见于40%病例,p16局灶或弥漫表达见于60%病例。
- AML中HMB45局灶或弥漫阳性见于76%病例,Melan-A阳性见于96%病例。
- HMB45和Melan-A在所检测的WDLS/DDLS及脂肪瘤中均不表达。
- WDLS/DDLS中MDM2局灶或弥漫表达见于91%病例,p16见于97%病例。
- 脂肪瘤中MDM2局灶表达见于14%病例、p16局灶表达见于67%病例,无脂肪瘤出现MDM2弥漫阳性。
关键数值与推荐
- AML:MDM2局灶40%,p16局灶/弥漫60%,HMB45局灶/弥漫76%,Melan-A 96%。
- WDLS/DDLS:MDM2局灶/弥漫91%,p16局灶/弥漫97%。
- 脂肪瘤:MDM2局灶14%,p16局灶67%,无MDM2弥漫阳性。
- HMB45与Melan-A在WDLS/DDLS及脂肪瘤中均不表达。
临床怎么用
- 对怀疑AML(尤其富脂肪型)与腹膜后WDLS或脂肪瘤鉴别困难时,联合检测HMB45、Melan-A、MDM2和p16并结合形态学判断。
- 结果不确定的病例应进一步行MDM2 FISH检测以辅助鉴别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angiomyolipoma (AML) arises primarily from the kidney but may grow into the retroperitoneal space mimicking a primary retroperitoneal tumor. Fine needle aspiration (FNA) and core needle biopsy of AML, particularly the fat-predominant variant, may be difficult to distinguish from retroperitoneal well-differentiated liposarcoma (WDLS) or lipoma. Commonly used immunomarkers, MDM2 and p16, have proven useful in diagnosing WDLS and dedifferentiated liposarcoma (DDLS), while HMB45 and Melan-A are melanocyte-related markers characteristically expressed in AML. In this study, we investigated the utility of MDM2 and p16 along with HMB45 and Melan-A immunohistochemical analysis in distinguishing AML from WDL/DDLS or lipoma. Immunohistochemically, AMLs demonstrated focal MDM2 expression (40% of cases) and focal/diffuse expression of p16 (60%). AMLs marked focally or diffusely with HMB45 (76% of cases) and Melan-A (96%). These latter two immunomarkers were not expressed in any of the WDLS/DDLSs or lipomas tested. WDLS/DDLSs showed focal/diffuse expression of MDM2 (91% of cases) and p16 (97%). While focal expression of MDM2 and p16 was observed in 14% and 67% of lipomas, respectively, no lipoma exhibited diffuse MDM2 positivity. In our hands, MDM2 expression by itself cannot exclude the diagnosis of AML or lipoma, and p16 alone is not helpful in separating AML and conventional lipoma from WDLS/DDLS. However, along with morphology, an immunohistochemical battery including HMB45, Melan-A, MDM2 and p16 are useful in distinguishing AML from WDLS/DDLS or lipoma. For equivocal cases, fluorescence in situ hybridization for MDM2 should be performed.
引用
- Lin X, Laskin WB, Lu X, et al. Expression of MDM2 and p16 in angiomyolipoma. Hum Pathol. 2018. PMID: 29432785. doi:10.1016/j.humpath.2018.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。